Bilateral gene therapy in children with autosomal recessive deafness 9: single-arm trial results
Hui Wang,Yuxin Chen,Jun Lv,Xiaoting Cheng,Qi Cao,Daqi Wang,Longlong Zhang,Biyun Zhu,Min Shen,Chunxin Xu,Mengzhao Xun,Zijing Wang,Honghai Tang,Shaowei Hu,Chong Cui,Luoying Jiang,Yanbo Yin,Luo Guo,Yi Zhou,Lei Han,Ziwen Gao,Jiajia Zhang,Sha Yu,Kaiyu Gao,Jinghan Wang,Bing Chen,Wuqing Wang,Zheng-Yi Chen,Huawei Li,Yilai Shu
DOI: https://doi.org/10.1038/s41591-024-03023-5
IF: 82.9
2024-06-06
Nature Medicine
Abstract:Gene therapy is a promising approach for hereditary deafness. We recently showed that unilateral AAV1-hOTOF gene therapy with dual adeno-associated virus (AAV) serotype 1 carrying human OTOF transgene is safe and associated with functional improvements in patients with autosomal recessive deafness 9 (DFNB9). The protocol was subsequently amended and approved to allow bilateral gene therapy administration. Here we report an interim analysis of the single-arm trial investigating the safety and efficacy of binaural therapy in five pediatric patients with DFNB9. The primary endpoint was dose-limiting toxicity at 6 weeks, and the secondary endpoint included safety (adverse events) and efficacy (auditory function and speech perception). No dose-limiting toxicity or serious adverse event occurred. A total of 36 adverse events occurred. The most common adverse events were increased lymphocyte counts (6 out of 36) and increased cholesterol levels (6 out of 36). All patients had bilateral hearing restoration. The average auditory brainstem response threshold in the right (left) ear was >95 dB (>95 dB) in all patients at baseline, and the average auditory brainstem response threshold in the right (left) ear was restored to 58 dB (58 dB) in patient 1, 75 dB (85 dB) in patient 2, 55 dB (50 dB) in patient 3 at 26 weeks, and 75 dB (78 dB) in patient 4 and 63 dB (63 dB) in patient 5 at 13 weeks. The speech perception and the capability of sound source localization were restored in all five patients. These results provide preliminary insights on the safety and efficacy of binaural AAV gene therapy for hereditary deafness. The trial is ongoing with longer follow-up to confirm the safety and efficacy findings. Chinese Clinical Trial Registry registration: ChiCTR2200063181.
biochemistry & molecular biology,cell biology,medicine, research & experimental